HCP Interactive SOA Tool

Schedule of Assessments
A study doctor discusses the Progress-AD Study with a study staff member, early Alzheimer's disease, slow memory loss.
Back

Screening and Baseline

Below is the schedule of assessments (SOA) for this stage of the study protocol (Protocol Amendment 01; 25 Apr 2024).

Visit 1 (Screening)

Some visits may be conducted over multiple days, where noted, for specific assessments.

Allowed interval: Up to 12 weeks prior to Day 1.

Participants may proceed to Day 1 as soon as all procedures are completed and eligibility has been reviewed.

Back

Visit 2 (Screening)

Visits may be conducted over multiple days, where noted, for specific assessments.

Allowed interval: Up to 12 weeks prior to Day 1.

Participants may proceed to Day 1 as soon as all screening and baseline procedures are completed and do not necessarily have to use up to 12 weeks before Day 1. Baseline procedures must be completed before Day 1.

Back

Visit 3 (Screening)

Visits may be conducted over multiple days, where noted, for specific assessments.

Allowed interval: Up to 12 weeks prior to Day 1.

Participants may proceed to Day 1 as soon as all screening and baseline procedures are completed and do not necessarily have to use up to 12 weeks before Day 1. Baseline procedures must be completed before Day 1.

Back

Visit 4 (Baseline)

Visits may be conducted over multiple days, where noted, for specific assessments.

Allowed interval: Up to 12 weeks prior to Day 1.

Participants may proceed to Day 1 as soon as all screening and baseline procedures are completed and do not necessarily have to use up to 12 weeks before Day 1. Baseline procedures must be completed before Day 1.

Intervention Period

(number of weeks since treatment start)

Below is the schedule of assessments (SOA) for this stage of the study protocol.

Back

Visit 5 (Day 1)

Participants may proceed to Day 1 as soon as all screening and baseline procedures are completed and do not necessarily have to use up to 12 weeks before Day 1. Baseline procedures must be completed before Day 1.

  • Reassess consent capacity and burden to participant at least every 6 months. (Refer to Section 10.1.3 of the protocol.)
  • Inclusion/exclusion criteria
  • Randomization

Examination, Vital Signs & ECG

COAs/PROs and C-SSRS

  • C-SSRS

Imaging

  • None

Review

Study Intervention Administration

Back

Visit 6 (Week 4)

Allowed interval: +/- 7 days

  • Reassess consent capacity and burden to participant at least every 6 months. (Refer to Section 10.1.3 of the protocol.)

Examination, Vital Signs & ECG

COAs/PROs and C-SSRS

Imaging

  • None

Review

Study Intervention Administration

Back

Visit 7 (Week 8)

Allowed interval: +/- 7 days

  • Reassess consent capacity and burden to participant at least every 6 months. (Refer to Section 10.1.3 of the protocol.)

Examination, Vital Signs & ECG

COAs/PROs and C-SSRS

  • C-SSRS

Imaging

  • None

Review

Study Intervention Administration

Back

Visit 8* (Week 12)

*Visit may be conducted over 2 to 3-day period.
Allowed interval: +/- 7 days

Back

Visit 9 (Week 16)

Allowed interval: +/- 7 days

  • Reassess consent capacity and burden to participant at least every 6 months. (Refer to Section 10.1.3 of the protocol.)

Examination, Vital Signs & ECG

COAs/PROs and C-SSRS

  • C-SSRS

Imaging

  • None

Review

Study Intervention Administration

Back

Visit 10 (Week 20)

Allowed interval: +/- 7 days

  • Reassess consent capacity and burden to participant at least every 6 months. (Refer to Section 10.1.3 of the protocol.)

Examination, Vital Signs & ECG

COAs/PROs and C-SSRS

  • C-SSRS

Imaging

  • None

Review

Study Intervention Administration

Back

Visit 12 (Week 28)

Allowed interval: +/- 7 days

  • Reassess consent capacity and burden to participant at least every 6 months. (Refer to Section 10.1.3 of the protocol.)

Examination, Vital Signs & ECG

COAs/PROs and C-SSRS

  • C-SSRS

Laboratory Assessments

  • None

Imaging

  • None

Review

Study Intervention Administration

Back

Visit 13 (Week 32)

Allowed interval: +/- 7 days

  • Reassess consent capacity and burden to participant at least every 6 months. (Refer to Section 10.1.3 of the protocol.)

Examination, Vital Signs & ECG

COAs/PROs and C-SSRS

  • C-SSRS

Laboratory Assessments

  • None

Imaging

  • None

Review

Study Intervention Administration

Back

Visit 14 (Week 36)

Allowed interval: +/- 7 days

  • Reassess consent capacity and burden to participant at least every 6 months. (Refer to Section 10.1.3 of the protocol.)

Examination, Vital Signs & ECG

COAs/PROs and C-SSRS

  • C-SSRS

Imaging

  • None

Review

Study Intervention Administration

Back

Visit 15 (Week 40)

Allowed interval: +/- 7 days

  • Reassess consent capacity and burden to participant at least every 6 months. (Refer to Section 10.1.3 of the protocol.)

Examination, Vital Signs & ECG

COAs/PROs and C-SSRS

  • C-SSRS

Laboratory Assessments

  • None

Imaging

  • None

Review

Study Intervention Administration

Back

Visit 16 (Week 44)

Allowed interval: +/- 7 days

  • Reassess consent capacity and burden to participant at least every 6 months. (Refer to Section 10.1.3 of the protocol.)

Examination, Vital Signs & ECG

COAs/PROs and C-SSRS

  • C-SSRS

Laboratory Assessments

Imaging

  • None

Review

Study Intervention Administration

Back

Visit 17* (Week 48)

*Visit may be conducted over 2 to 3-day period.
Allowed interval: +/- 7 days

  • Reassess consent capacity and burden to participant at least every 6 months. (Refer to Section 10.1.3 of the protocol.)

Examination, Vital Signs & ECG

COAs/PROs and C-SSRS

  • C-SSRS

Imaging

  • None

Review

Study Intervention Administration

Back

Visit 19 (Week 56)

Allowed interval: +/- 7 days

  • Reassess consent capacity and burden to participant at least every 6 months. (Refer to Section 10.1.3 of the protocol.)

Examination, Vital Signs & ECG

COAs/PROs and C-SSRS

  • C-SSRS

Laboratory Assessments

  • None

Imaging

  • None

Review

Study Intervention Administration

Back

Visit 20 (Week 60)

Allowed interval: +/- 7 days

  • Reassess consent capacity and burden to participant at least every 6 months. (Refer to Section 10.1.3 of the protocol.)

Examination, Vital Signs & ECG

COAs/PROs and C-SSRS

  • C-SSRS

Laboratory Assessments

  • None

Imaging

  • None

Review

Study Intervention Administration

Back

Visit 22 (Week 68)

Allowed interval: +/- 7 days

  • Reassess consent capacity and burden to participant at least every 6 months. (Refer to Section 10.1.3 of the protocol.)

Examination, Vital Signs & ECG

COAs/PROs and C-SSRS

  • C-SSRS

Laboratory Assessments

Imaging

  • None

Review

Study Intervention Administration

Back

Visit 23* (Week 72)

*Visit may be conducted over 2 to 3-day period.
Allowed interval: +/- 7 days

  • Reassess consent capacity and burden to participant at least every 6 months. (Refer to Section 10.1.3 of the protocol.)

Examination, Vital Signs & ECG

COAs/PROs and C-SSRS

Imaging

  • None

Review

Study Intervention Administration

Back

Early Study Discontinuation

Within 4 weeks post last dose.

  • Reassess consent capacity and burden to participant at least every 6 months. (Refer to Section 10.1.3 of the protocol.)

Examination, Vital Signs & ECG

COAs/PROs and C-SSRS

  • C-SSRS

Imaging

Review

Study Intervention Administration

  • None
Back

Visit 25 (Follow-up)

*Visit may be conducted over 2 to 3-day period.

  • Reassess consent capacity and burden to participant at least every 6 months. (Refer to Section 10.1.3 of the protocol.)

Examination, Vital Signs & ECG

COAs/PROs and C-SSRS

  • C-SSRS

Imaging

  • MRI (safety, volumetric)

Review

Study Intervention Administration

  • None